Axon Enterprise (AXON) Expected to Announce Quarterly Earnings on Monday

Axon Enterprise (NASDAQ:AXON) is anticipated to issue its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of $1.84 per share and revenue of $876.4250 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.90 million. During the same period in the previous year, the business earned $1.47 earnings per share. The firm’s revenue for the quarter was up 33.7% on a year-over-year basis. On average, analysts expect Axon Enterprise to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock opened at $502.34 on Monday. The stock has a 50 day moving average of $483.26 and a 200 day moving average of $478.81. Axon Enterprise has a 12 month low of $339.01 and a 12 month high of $885.91. The firm has a market cap of $40.49 billion, a PE ratio of 201.74, a PEG ratio of 10.25 and a beta of 1.38. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49.

Analyst Ratings Changes

AXON has been the topic of a number of research reports. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 10th. UBS Group cut their target price on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. Barclays reduced their price target on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Finally, Morgan Stanley set a $600.00 target price on shares of Axon Enterprise in a research report on Thursday, May 7th. Fifteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $725.25.

Insider Buying and Selling at Axon Enterprise

In other news, insider Isaiah Fields sold 2,000 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $400.00, for a total value of $800,000.00. Following the sale, the insider directly owned 52,813 shares in the company, valued at approximately $21,125,200. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Patrick W. Smith sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total value of $10,000,000.00. Following the sale, the chief executive officer directly owned 3,060,997 shares of the company’s stock, valued at $1,530,498,500. This represents a 0.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 58,989 shares of company stock valued at $30,527,983. 4.20% of the stock is owned by company insiders.

Institutional Trading of Axon Enterprise

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sunbelt Securities Inc. lifted its position in shares of Axon Enterprise by 324.1% during the fourth quarter. Sunbelt Securities Inc. now owns 123 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 94 shares during the last quarter. Corient Private Wealth LLC boosted its stake in shares of Axon Enterprise by 579.2% during the fourth quarter. Corient Private Wealth LLC now owns 65,447 shares of the biotechnology company’s stock valued at $37,169,000 after purchasing an additional 55,811 shares during the period. Strive Financial Group LLC bought a new position in shares of Axon Enterprise in the fourth quarter worth about $41,000. Raymond James Financial Inc. grew its holdings in shares of Axon Enterprise by 0.8% in the fourth quarter. Raymond James Financial Inc. now owns 404,990 shares of the biotechnology company’s stock worth $231,015,000 after purchasing an additional 3,136 shares during the last quarter. Finally, Vident Advisory LLC lifted its holdings in Axon Enterprise by 15.3% during the 4th quarter. Vident Advisory LLC now owns 4,145 shares of the biotechnology company’s stock valued at $2,354,000 after buying an additional 550 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.